Skip to main content
SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. logo

SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. — Investor Relations & Filings

Ticker · 688163 ISIN · CNE1000059X8 LEI · 8368001TREMN2G5DDS70 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 335 across all filing types
Latest filing 2024-04-26 Remuneration Information
Country CN China
Listing Shanghai Stock Exchange 688163

About SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD.

https://www.serum-china.com.cn/en/

Shanghai Serum Bio-Technology Co., Ltd. is a specialized biopharmaceutical enterprise focused on the research, development, and manufacturing of therapeutic biological products. The company primarily produces a range of antiserums and antitoxins, including specialized antivenoms for various snake species, tetanus antitoxins, and rabies immunoglobulins. Its product portfolio supports emergency medical care and infectious disease management. The organization maintains advanced production facilities compliant with Good Manufacturing Practice (GMP) standards to ensure the safety and efficacy of its biological treatments. By leveraging biotechnological innovation, the company serves clinical needs in healthcare sectors, providing critical life-saving interventions for envenomation and acute bacterial toxins.

Recent filings

Filing Released Lang Actions
赛伦生物：关于2024年度公司董事、监事、高级管理人员薪酬方案的公告
Remuneration Information Classification · 95% confidence The document is an announcement from Shanghai SAILUN Biotech Co., Ltd. regarding the 2024 remuneration scheme for the company's directors, supervisors, and senior management. It details the salary standards and payment arrangements for these roles, including independent directors, non-independent directors, supervisors, and senior management personnel. The document also mentions that the remuneration proposals will be submitted to the shareholders' meeting for approval. There is no financial data, audit information, or report content; rather, it is a disclosure about management compensation plans. This fits the definition of Remuneration Information (DEF 14A), which covers reports detailing compensation for top executives and directors.
2024-04-26 Chinese
赛伦生物：关于续聘2024年度审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the reappointment of the audit firm for the 2024 fiscal year. It details the qualifications, integrity, and independence of the audit firm, as well as the procedures followed by the audit committee, board of directors, and supervisory board in approving the reappointment. The document does not contain any financial statements or audit reports themselves, but rather is a formal announcement about the selection and continuation of the audit firm. The document length is 3122 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document fits the category of Audit Report / Information (AR), as it relates to audit firm information and appointment, but is not a full annual report or audit report itself. However, since it is specifically about the audit firm appointment and related information, AR is the most appropriate classification rather than Regulatory Filings (RNS) or Report Publication Announcement (RPA). FY 2024
2024-04-26 Chinese
方正证券承销保荐有限责任公司关于上海赛伦生物技术股份有限公司2023年度募集资金存放与实际使用情况的专项核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed special audit opinion report by the sponsor (方正证券承销保荐有限责任公司) on the 2023 annual fundraising funds deposit and actual usage situation of Shanghai Sailun Biotechnology Co., Ltd. It includes detailed financial figures on fundraising, usage, balances, and compliance with regulatory requirements. The document references regulatory approvals, fundraising amounts, usage breakdowns, and compliance with listing rules and supervisory guidelines. It is a standalone audit-related report focusing on the verification and opinion on the fundraising funds usage, not a full annual report or earnings release. It is not a simple announcement or publication notice but contains substantive financial and compliance information. Therefore, it fits the category of an Audit Report / Information (AR). The document length (6533 characters) and content support this classification with high confidence. FY 2023
2024-04-26 Chinese
赛伦生物：2023年年度报告摘要
Annual Report Classification · 100% confidence The document is titled '2023 年年度报告摘要' which translates to '2023 Annual Report Summary'. It contains detailed financial data for the year 2023, including total assets, net profit, revenue, and quarterly financial data. It also includes comprehensive business descriptions, industry analysis, risk factors, shareholder information, and dividend distribution plans. The document is lengthy (over 12,000 characters) and contains substantive financial statements and management discussion. It is clearly a full annual report or a summary derived from the full annual report, not merely an announcement or a presentation. Therefore, the document fits the definition of an Annual Report (10-K). FY 2023
2024-04-26 Chinese
赛伦生物：2023年度董事会审计委员会履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2023年度董事会审计委员会履职情况报告" which translates to "2023 Annual Report on the Board Audit Committee's Performance." It details the audit committee's activities, meetings, evaluations of external and internal audits, financial report reviews, and internal control assessments for the year 2023. The content focuses on the audit committee's duties and oversight rather than presenting full financial statements or comprehensive company performance data. The document length is 2297 characters, which is relatively short and focused on committee activities rather than a full annual report. This type of document is a standalone audit-related report describing audit committee work and audit results, fitting the definition of an Audit Report / Information (AR) rather than a full Annual Report (10-K) or other categories. Therefore, the appropriate classification is AR with high confidence. FY 2023
2024-04-26 Chinese
赛伦生物：2023年度独立董事述职报告（章建康，离任）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2023 of Shanghai Sairen Biotechnology Co., Ltd. It details the independent director's duties, attendance at board and shareholder meetings, communication with audit firms, and oversight activities during the year. It includes information about board appointments and remuneration oversight but does not contain financial statements or detailed financial data. The document is a report on the independent director's activities and compliance with governance duties rather than a full annual report or audit report. This fits best under Board/Management Information (MANG), which covers announcements related to board or senior management changes and related reports. The document length is 3548 characters, which is relatively short and focused on director duties rather than comprehensive financial reporting. Therefore, the classification is MANG with high confidence.
2024-04-26 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.